Analysts expect that Reata Pharmaceuticals, Inc. (NASDAQ:RETA) will report sales of $12.59 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Reata Pharmaceuticals’ earnings. The highest sales estimate is $12.81 million and the lowest is $12.45 million. Reata Pharmaceuticals posted sales of $12.55 million during the same quarter last year, which indicates a positive year over year growth rate of 0.3%. The company is scheduled to announce its next earnings results on Monday, November 13th.

On average, analysts expect that Reata Pharmaceuticals will report full year sales of $12.59 million for the current year, with estimates ranging from $45.00 million to $51.15 million. For the next year, analysts expect that the firm will post sales of $50.06 million per share, with estimates ranging from $49.46 million to $50.42 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Reata Pharmaceuticals.

A number of research analysts have weighed in on the company. Zacks Investment Research lowered Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, July 18th. Piper Jaffray Companies lifted their target price on Reata Pharmaceuticals from $53.00 to $60.00 and gave the company a “buy” rating in a report on Monday, July 24th. Citigroup Inc. reaffirmed a “buy” rating and set a $87.00 target price (up previously from $39.00) on shares of Reata Pharmaceuticals in a report on Tuesday, July 25th. Stifel Nicolaus reaffirmed a “buy” rating and set a $50.00 target price (up previously from $38.00) on shares of Reata Pharmaceuticals in a report on Tuesday, July 25th. Finally, Robert W. Baird reaffirmed an “outperform” rating and set a $47.00 target price (up previously from $43.00) on shares of Reata Pharmaceuticals in a report on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $54.71.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/03/12-59-million-in-sales-expected-for-reata-pharmaceuticals-inc-reta-this-quarter.html.

Several hedge funds and other institutional investors have recently modified their holdings of RETA. Nationwide Fund Advisors lifted its position in Reata Pharmaceuticals by 38.1% in the 2nd quarter. Nationwide Fund Advisors now owns 4,368 shares of the company’s stock worth $138,000 after buying an additional 1,206 shares during the last quarter. Wells Fargo & Company MN lifted its position in Reata Pharmaceuticals by 37.4% in the 2nd quarter. Wells Fargo & Company MN now owns 5,591 shares of the company’s stock worth $176,000 after buying an additional 1,521 shares during the last quarter. California State Teachers Retirement System lifted its position in Reata Pharmaceuticals by 20.8% in the 2nd quarter. California State Teachers Retirement System now owns 15,125 shares of the company’s stock worth $479,000 after buying an additional 2,600 shares during the last quarter. Alliancebernstein L.P. lifted its position in Reata Pharmaceuticals by 29.1% in the 2nd quarter. Alliancebernstein L.P. now owns 14,200 shares of the company’s stock worth $449,000 after buying an additional 3,200 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in Reata Pharmaceuticals by 18.1% in the 1st quarter. Bank of New York Mellon Corp now owns 22,213 shares of the company’s stock worth $503,000 after buying an additional 3,407 shares during the last quarter. 15.68% of the stock is owned by institutional investors.

About Reata Pharmaceuticals

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

Get a free copy of the Zacks research report on Reata Pharmaceuticals (RETA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Reata Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.